Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BLD-0409 (cudetaxestat) was well tolerated and showed no reports of treatment-related serious adverse events, including when co-administered with either pirfenidone or nintedanib, in healthy volunteers.
Lead Product(s): Cudetaxestat,Pirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2022
Details:
BLD-0409 (cudetaxestat), a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial in patients with idiopathic pulmonary fibrosis.
Lead Product(s): Cudetaxestat,Pirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
BLD-0409 (cudetaxestat), a non-competitive, reversible inhibitor of autotaxin, has demonstrated direct anti-fibrotic activity and differentiating preclinical and biochemical characteristics which support potential for a treatment profile in lung and liver fibrosis.
Lead Product(s): Cudetaxestat
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biotech Acquisition Company
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
No significant drug-drug interaction (DDI) seen with BLD-0409 (cudetaxestat) in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF).
Lead Product(s): Cudetaxestat,Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
U.S. FDA provides feedback necessary to proceed into a phase 2 proof of concept (PoC)/dose ranging study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in patients with idiopathic pulmonary fibrosis (IPF).
Lead Product(s): Cudetaxestat,Pirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
New data from a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor co-administered with either of two approved drugs for IPF (pirfenidone and nintedanib) will be presented.
Lead Product(s): Cudetaxestat,Pirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biotech Acquisition Company
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
Cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF. Phase 1 clinical study to assess effect of cudetaxestat on pharmacokinetics of two approved therapies for idiopathic pulmonary fibrosis (IPF).
Lead Product(s): Cudetaxestat
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
BLD-2660 is a small-molecule investigational medicine designed to target a specific group of cysteine proteases called dimeric calpains (calpains 1, 2 and 9). Over-activity of dimeric calpains leads to inflammation and fibrosis.
Lead Product(s): BLD-2660
Therapeutic Area: Infections and Infectious Diseases Product Name: BLD-2660
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
The Company has developed a diversified small molecule portfolio, including two clinical stage assets (BLD-2660 and BLD-0409) and several preclinical stage assets, through a combination of in-house drug discovery and selective in-licensing.
Lead Product(s): BLD-2660
Therapeutic Area: Infections and Infectious Diseases Product Name: BLD-2660
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020